Lotus Pharmaceutical Announces Acquisition of Product Rights for 'Matterhorn' in the Korean Market via Subsidiary Alvogen Korea

Reporting Date: May 21, 2026 Company Code: 1795 Company Name: Lotus Pharmaceutical

The Board of Directors of Lotus Pharmaceutical has approved the purchase of intellectual property, marketing authorizations, and product technology related to the product 'Matterhorn' for the Korean market by its subsidiary, Alvogen Korea, from OM PHARMA SA.

1. Target: Intellectual property, marketing authorizations, and product technology related to the product 'Matterhorn' for sale in the Korean market held by OM PHARMA SA. 2. Total Transaction Value: 69 million USD. 3. Counterparty: OM PHARMA SA (Not a related party). 4. Purpose: Optimization of product portfolio. 5. Source of Funds: Internal capital and bank loans. 6. Decision Process: Decided after Board of Directors' approval, referencing a valuation report provided by an independent expert. 7. Others: The transaction amount was calculated based on the Taiwan Bank exchange rate of May 19, 2026 (1 USD = 31.65 TWD).